HUANG Yuan1, 2, LIU Guo-en1, 3, GAO Chen1, WANG Chang-zhi1, 4, REN Xiao-xiao1, 4, LIU Yue-hua1*
1. China Center for Health Economic Research, Peking University, Beijing 100871, China; 2. West China School of Public Health, Sichuan University, Chengdu 610041, China; 3. National School of Development, Peking University, Beijing 100871, China; 4. School of Business Administration, Shenyang Pharmaceutical University, Shenyang 110016, China
Abstract��
OBJECTIVE To evaluate the efficacy and safety of paliperidone palmitate long-acting injection(PP-LAI) in the treatment of schizophrenia. METHODS Published studies concerning PP-LAI for schizophrenia were searched systemically and assessed by Jadad items. RevMan 5.2 software was used for data analysis and for calculating effectiveness and their 95%CIs. RESULTS Twelve Clinical random control trials including 39 analytic sets were selected for Meta-analysis. The incidence of efficient cases in PP-LAI group was 1.7(95��CI: 1.50-1.91) times higher than that in placebo group(Z=8.55, P<0.01) and equaled to the rate in risperidone group(RR=1, 95%CI: 0.88-1.13). Compared with the control group of placebo(RR=1.01, 95%CI: 0.97-1.05) and risperidone(RR=1.07, 95%CI: 0.98-1.16), PP-LAI seemed to be well tolerated, with the same incidence of adverse events.CONCLUSION Paliperidone palmitate has certain efficacy and safety in the treatment of schizophrenia.
HUANG Yuan-,
,
LIU Guo-�� etc
.Efficacy and Safety of Paliperidone Palmitate in the Treatment of Schizophrenia: a Meta-Analysis[J] Chinese Pharmaceutical Journal, 2014,V49(6): 517-522
��
[1]
PHILLIPS M R, ZHANG J X, SHI Q C, et al. Prevalence, treatment, and associated disability of mental disorders in four provinces in China during 2001-05:An epidemiological survey. Lancet, 2009, 373(9680): 2041-2053.[2] NASRALLAH H A. The case for long-acting antipsychotic agents in the post-CATIE era. Acta Psychiatr Scand, 2007, 115(4): 260-267.[3] ALPHS L, BOSSIE C A, SLIWA J K, et al. Onset of efficacy with acute long-acting injectable paliperidone palmitate treatment in markedly to severely ill patients with schizophrenia:Post hoc analysis of a randomized, double-blind clinical trial. Ann Gen Psychiatry, 2011, 10(1):12.[4] GOPAL S, HOUGH D W, XU H, et al. Efficacy and safety of paliperidone palmitate in adult patients with acutely symptomatic schizophrenia: A randomized, double-blind, placebo-controlled, dose-response study. Int Clin Psycho Pharmacol, 2010, 25(5): 247-256.[5] HOUGH D, GOPAL S, VIJAPURKAR U, et al. Paliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: A randomized, double-blind, placebo-controlled study. Schizophr Res, 2010, 116(2-3): 107-117.[6] KRAMER M, LITMAN R, HOUGH D, et al. Paliperidone palmitate, a potential long-acting treatment for patients with schizophrenia. Results of a randomized, double-blind, placebo-controlled efficacy and safety study. Int J Neuropsychopharmacol, 2010, 13(5): 635-647.[7] NASRALLAH H A, GOPAL S, GASSMANN-MAYER C, et al. A controlled, evidence-based trial of paliperidone palmitate, along-acting injectable antipsychotic, in schizophrenia. Neuropsychopharmacology, 2010, 35(10):2072-2082.[8] PANDINA G J, LINDENMAYER J P, LULL J, et al. A randomized, placebo-controlled study to assess the efficacy and safety of 3 doses of paliperidone palmitate in adults with acutely exacerbated schizophrenia. J Clin Psychopharmacol, 2010, 30(3):235-244.[9] SLIWA J K, BOSSIE C A, MA Y W, et al. Effects of acute paliperidone palmitate treatment in subjects with schizophrenia recently treated with oral risperidone. Schizophr Res, 2011, 132(1):28-34. ALPHS L, BOSSIE C A, SLIWA J K, et al. Paliperidone palmitate and risperidone long-acting injectable in subjects with schizophrenia recently treated with oral risperidone or other oral antipsychotics. Neuropsychiatr Dis Treat, 2013, 9:341-350. FLEISCHHACKER W W, GOPAL S, LANE R, et al. A randomized trial of paliperidone palmitate and risperidone long-acting injectable in schizophrenia. Int J Neuropsychopharmacol, 2012, 15(1): 107-118. GOPAL S, PANDINA G, LANE R, et al. A post-hoc comparison of paliperidone palmitate to oral risperidone during initiation of long-acting risperidone injection in patients with acute schizophrenia. Innov Clin Neurosci, 2011, 8(8):26-33. LI H, RUI Q, NING X, et al. A comparative study of paliperidone palmitate and risperidone long-acting injectable therapy in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry, 2011, 35(4):1002-1008. PANDINA G, LANE R, GOPAL S, et al. A double-blind study of paliperidone palmitate and risperidone long-acting injectable in adults with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry, 2011, 35(1):218-226.
2014, Vol. 49 
